Inventor · disambiguated record
Qun Du
Also filed as: DU QUN
9 granted patents·11 pending applications·29 citations·filing 2015–2024
83Inventor score
Files withMEDIMMUNE LLC7ASTRAZENECA UK LTD5BOSTON PHARMACEUTICALS INC4ASTRAZENECA AB3FUSION PHARMACEUTICALS INC1
Top patents by PatentIndex Score
20 records- 0194US9738723B2Humanized anti-OX40 antibodies and uses thereofMEDIMMUNE LLC·Filed 2015·Granted Aug 22, 2017·20 cites·24 claims
- 0289US11059884B2Antibodies directed against Staphylococcus aureus leukotoxinsMEDIMMUNE LLC·Filed 2019·Granted Jul 13, 2021·4 cites·28 claims
- 0387US11578119B2Antibodies directed against Staphylococcus aureus leukotoxinsMEDIMMUNE LLC·Filed 2021·Granted Feb 14, 2023·1 cites·20 claims
- 0485US11168133B2Combinations of anti-Staphylococcus aureus antibodiesMEDIMMUNE LLC·Filed 2019·Granted Nov 9, 2021·3 cites·22 claims
- 0575US2023201346A1Binding molecules specific for il-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0673US10022443B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2015·Granted Jul 17, 2018·1 cites·17 claims
- 0772US2024360226A1Antibody molecules and conjugatesASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0871US12065496B2Antibody molecules and conjugatesASTRAZENECA AB·Filed 2022·Granted Aug 20, 2024·0 cites·27 claims
- 0967US11529415B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·0 cites·14 claims
- 1067US10588969B2Antibodies specific for IL-21 and uses thereofBOSTON PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·0 cites·14 claims
- 1166US2024182548A1Sars-cov-2 antibodies and methods of selecting and using the sameASTRAZENECA UK LTD·Filed 2023·Application pending·0 cites
- 1265US2025115678A1T cell binding compositions and methodsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 1365US2024092875A1Sars-cov-2 antibodies for treatment and prevention of covid-19ASTRAZENECA UK LTD·Filed 2023·Application pending·0 cites
- 1463US2022089699A1Combinations of anti-staphylococcus aureus antibodiesMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 1556US10150815B2Method of treating cancer with humanized anti-OX40 antibodiesMEDIMMUNE LLC·Filed 2017·Granted Dec 11, 2018·0 cites·8 claims
- 1656US2022041694A1Sars-cov-2 antibodies for treatment and prevention of covid-19ASTRAZENECA UK LTD·Filed 2021·Application pending·0 cites
- 1756US2019169303A1Humanized Anti-OX40 Antibodies and Uses ThereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 1855US2021355196A1Sars-cov-2 antibodies and methods of selecting and using the sameASTRAZENECA UK LTD·Filed 2021·Application pending·0 cites
- 1954US2025121104A1Egfr-cmet-targeted compounds and uses thereofFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2048US2023279078A1Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the sameASTRAZENECA UK LTD·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →